CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy.

TitleCD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy.
Publication TypeJournal Article
Year of Publication2016
AuthorsJudge CJ, Sandberg JK, Funderburg NT, Sherman KE, Butt AA, Kang M, Landay AL, Lederman MM, Anthony DD
JournalJ Acquir Immune Defic Syndr
Date Published2016 Jun 1
ISSN1944-7884
Abstract

During HIV+HCV+ co-infection CD14CD16-monocytes produce soluble immune-activation markers that predict disease-progression and poor IFNα-treatment response. We evaluated relationships among immune-activation, monocyte phenotype, CD4-memory T-cells and HCV-, CMV- and CMV/EBV/Influenza (CEF)-specific IFNγ-response, before and during IFNα-treatment. Effector-memory and central-memory CD4-T-cell frequencies were lower in HCV+HIV+ than uninfected-donors, and correlated negatively with HCV-level, CD14CD16-monocytes and plasma sCD14. sCD14 and CD14CD16 monocytes negatively correlated with IFNα-dependent HCV-decline. sCD14 negatively associated with and CD4 effector-memory T-cells positively-associated with CEF-specific IFNγ-response. These data support a role for memory-CD4 T-cells in HCV-containment, and link immune-activation and CD14CD16-monocyte frequency to failure of interferon-dependent HCV-clearance.

DOI10.1097/QAI.0000000000001104
Alternate JournalJ. Acquir. Immune Defic. Syndr.
PubMed ID27258231
Grant ListU01 AI068634 / AI / NIAID NIH HHS / United States
U01 AI068636 / AI / NIAID NIH HHS / United States
UM1 AI068634 / AI / NIAID NIH HHS / United States